Highlights
– Pemvidutide, a once‑weekly dual GLP‑1 and glucagon receptor agonist, produced large reductions in liver fat (up to ~75% relative reduction) over 24 weeks in MASLD patients and caused small but statistically significant reductions in AI‑quantified fibrosis in adults with MASH and F2–F3 disease.
– The IMPACT phase 2 study reported absolute reductions in AI‑measured fibrosis area of −0.40% (1.2 mg) and −0.69% (1.8 mg) vs placebo at 24 weeks; a further MASLD extension showed dose‑dependent liver fat normalization in a majority at the 1.8 mg dose.
